UCB gets FDA approval to market Keppra to treat adolescent seizures

By Elaine Rigoli

Tampa, Fla., Aug. 23 - UCB announced that the Food and Drug Administration has approved the use of Keppra (levetiracetam) as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy.

Keppra is prescribed as an add-on therapy in the treatment of partial onset seizures in adults and children four years of age and older with epilepsy.

The company said this new indication represents the first U.S. approval for Keppra for the treatment of a generalized seizure type in epilepsy patients.

The company said juvenile myoclonic epilepsy is a common epilepsy syndrome that usually starts between the ages of 12 and 18 and accounts for about 10% of all cases of epilepsy.

UCB is a biopharmaceutical company located in Brussels, Belgium.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.